OptiNose, Inc. (OPTN)
USD 9.27
(0.98%)
USD 9.27
(0.98%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -15.55 Million USD | 60.02% |
| 2022 | -57.45 Million USD | 15.88% |
| 2021 | -65.67 Million USD | 23.81% |
| 2020 | -85.32 Million USD | 8.77% |
| 2019 | -99.32 Million USD | 4.63% |
| 2018 | -96.89 Million USD | -106.55% |
| 2017 | -48.36 Million USD | -284.71% |
| 2016 | 25.4 Million USD | 196.13% |
| 2015 | -27.42 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -7.99 Million USD | -89.61% |
| 2024 Q2 | -6.46 Million USD | 71.7% |
| 2023 Q3 | -1.69 Million USD | 59.4% |
| 2023 Q4 | -2.39 Million USD | -41.15% |
| 2023 Q2 | -4.17 Million USD | 70.96% |
| 2023 FY | - USD | 60.02% |
| 2023 Q1 | -14.36 Million USD | -71.95% |
| 2022 Q4 | -8.35 Million USD | 21.23% |
| 2022 Q3 | -10.6 Million USD | 30.08% |
| 2022 Q2 | -15.17 Million USD | 28.24% |
| 2022 Q1 | -21.14 Million USD | -81.2% |
| 2022 FY | - USD | 15.88% |
| 2021 Q3 | -12.87 Million USD | 33.57% |
| 2021 Q2 | -19.38 Million USD | 11.91% |
| 2021 Q1 | -22 Million USD | -7.59% |
| 2021 FY | - USD | 23.81% |
| 2021 Q4 | -11.66 Million USD | 9.39% |
| 2020 Q4 | -20.45 Million USD | -17.68% |
| 2020 Q2 | -22.31 Million USD | 13.0% |
| 2020 Q3 | -17.38 Million USD | 22.1% |
| 2020 FY | - USD | 8.77% |
| 2020 Q1 | -25.64 Million USD | -11.88% |
| 2019 FY | - USD | 4.63% |
| 2019 Q2 | -24.66 Million USD | 5.89% |
| 2019 Q1 | -26.21 Million USD | -6.04% |
| 2019 Q4 | -22.92 Million USD | -20.87% |
| 2019 Q3 | -18.96 Million USD | 23.12% |
| 2018 Q1 | -28.22 Million USD | -43.31% |
| 2018 FY | - USD | -106.55% |
| 2018 Q4 | -24.71 Million USD | -9.29% |
| 2018 Q3 | -22.61 Million USD | -1.7% |
| 2018 Q2 | -22.24 Million USD | 21.21% |
| 2017 Q1 | -7.18 Million USD | -55.23% |
| 2017 Q2 | -8.28 Million USD | -15.26% |
| 2017 Q3 | -13.06 Million USD | -57.71% |
| 2017 Q4 | -19.69 Million USD | -50.75% |
| 2017 FY | - USD | -284.71% |
| 2016 FY | - USD | 196.13% |
| 2016 Q2 | -4.43 Million USD | -111.01% |
| 2016 Q3 | -5.2 Million USD | -17.23% |
| 2016 Q4 | -4.63 Million USD | 11.03% |
| 2016 Q1 | 40.3 Million USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 90.209% |
| PainReform Ltd. | -9.56 Million USD | -62.535% |
| Alvotech | -484.86 Million USD | 96.792% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 105.044% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 114.227% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 1415.821% |
| Journey Medical Corporation | 1.92 Million USD | 909.63% |
| Dynavax Technologies Corporation | 9.66 Million USD | 260.904% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 89.639% |
| Bright Green Corporation | - USD | Infinity% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 109.548% |
| Embecta Corp. | 245.4 Million USD | 106.338% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -306.676% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -306.676% |
| SCYNEXIS, Inc. | 73.47 Million USD | 121.167% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -269.266% |
| Silver Spike Investment Corp. | 7.34 Million USD | 311.891% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -561.545% |
| Alpha Teknova, Inc. | -25.53 Million USD | 39.101% |
| Safety Shot Inc | -12.18 Million USD | -27.639% |
| Procaps Group, S.A. | 104.02 Million USD | 114.951% |
| Cosmos Health Inc. | -17.06 Million USD | 8.843% |
| Theratechnologies Inc. | -10.31 Million USD | -50.813% |
| Harrow Health, Inc. | 9.72 Million USD | 259.961% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -243.713% |
| Biofrontera Inc. | -18.45 Million USD | 15.716% |
| DURECT Corporation | -24.68 Million USD | 36.992% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 115.828% |
| Cronos Group Inc. | -72.14 Million USD | 78.443% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 98.318% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 56.895% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 159.213% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 143.166% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -296.522% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -2087.944% |
| Radius Health, Inc. | 38.31 Million USD | 140.598% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -383.753% |
| ProPhase Labs, Inc. | -14.82 Million USD | -4.896% |
| Phibro Animal Health Corporation | 84.6 Million USD | 118.383% |
| Procaps Group S.A. | 104.02 Million USD | 114.951% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -85.133% |
| Viatris Inc. | 3.51 Billion USD | 100.442% |
| Rockwell Medical, Inc. | -4.69 Million USD | -231.338% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -1436.858% |
| SIGA Technologies, Inc. | 84.15 Million USD | 118.48% |
| Tilray Brands, Inc. | -72.84 Million USD | 78.649% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 2015.394% |
| Shineco, Inc. | -26.55 Million USD | 41.429% |
| PetIQ, Inc. | 81.48 Million USD | 119.087% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -329.923% |
| Incannex Healthcare Limited | -18.5 Million USD | 15.948% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 103.738% |
| Alimera Sciences, Inc. | 7.27 Million USD | 313.758% |
| Assertio Holdings, Inc. | -222.44 Million USD | 93.008% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -289.736% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 7.445% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 22.355% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 89.57% |
| Hempacco Co., Inc. | -12.77 Million USD | -21.762% |
| Talphera, Inc. | -9.84 Million USD | -58.027% |
| Alvotech | -484.86 Million USD | 96.792% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 120.068% |
| Lantheus Holdings, Inc. | 491 Million USD | 103.168% |
| Currenc Group, Inc. | -1.9 Million USD | -718.332% |
| Kamada Ltd. | 21.53 Million USD | 172.225% |
| Indivior PLC | 66 Million USD | 123.565% |
| Evoke Pharma, Inc. | -7.29 Million USD | -113.28% |
| Flora Growth Corp. | -45.87 Million USD | 66.093% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 22.355% |
| Evolus, Inc. | -41.81 Million USD | 62.801% |
| HUTCHMED (China) Limited | 25.52 Million USD | 160.925% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 106.441% |
| Akanda Corp. | -27.73 Million USD | 43.924% |